|
Mitomycin for Injection
» Mitomycin for Injection contains not less than 90.0 percent and not more than 120.0 percent of the labeled amount of mitomycin (C15H18N4O5).
Packaging and storage
Preserve in Containers for Sterile Solids as described under Injections
Constituted solution
At the time of use, it meets the requirements for Constituted Solutions under Injections
Identification
Dissolve a quantity in water, and dilute with water to obtain a solution having a concentration of about 1 mg of mitomycin per mL. Apply 2 µL of this solution and 2 µL of a Standard solution of USP Mitomycin RS, similarly prepared to a suitable thin-layer chromatographic plate (see Chromatography
Bacterial endotoxins
Sterility
pH
Water, Method Ia
Other requirements
It meets the requirements under Injections
Assay
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system
Prepare as directed in the Assay under Mitomycin.
Assay preparation
Add an accurately measured volume of N,N-dimethylacetamide to 1 container of Mitomycin for Injection to obtain a solution having a concentration of about 0.5 mg of mitomycin per mL.
Procedure
Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of mitomycin (C15H18N4O5) in the container of Mitomycin for Injection taken by the formula:
(CP/1000)(L/D)(rU / rS)
in which C is the concentration, in mg per mL, of USP Mitomycin RS in the Standard preparation; P is the stated potency, in µg per mg, of USP Mitomycin RS; L is the labeled quantity, in mg, of mitomycin in the container; D is the concentration, in mg per mL, of mitomycin in the Assay preparation, on the basis of the labeled quantity and the extent of dilution; and rU and rS are the peak areas obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 3937
Pharmacopeial Forum: Volume No. 29(4) Page 1053
|